--- title: "Ultragenyx Shareholders Approve Incentive Plan, Elect Directors" type: "News" locale: "en" url: "https://longbridge.com/en/news/286809118.md" description: "Ultragenyx Pharmaceutical shareholders approved the 2023 Incentive Plan and elected Class I directors at the Annual Meeting on May 14, 2026. The plan aims to enhance employee retention and align management with shareholder interests. Shareholders also ratified Ernst & Young LLP as the independent auditor for 2026 and expressed support for the executive compensation program. The latest analyst rating for RARE stock is a Buy with a $79.00 price target, though concerns about financial performance persist." datetime: "2026-05-18T18:53:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286809118.md) - [en](https://longbridge.com/en/news/286809118.md) - [zh-HK](https://longbridge.com/zh-HK/news/286809118.md) --- # Ultragenyx Shareholders Approve Incentive Plan, Elect Directors ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Ultragenyx Pharmaceutical ( (RARE) ) has issued an announcement. At its Annual Meeting of Stockholders held on May 14, 2026, Ultragenyx Pharmaceutical shareholders approved the Third Amended and Restated 2023 Incentive Plan, reinforcing the company’s long-term equity-based compensation framework for employees and executives. The incentive plan approval is a key element of Ultragenyx’s capital and talent strategy, aiming to support retention and alignment of management with shareholder interests in a competitive rare-disease biotech market. At the same meeting, stockholders elected Class I directors Emil D. Kakkis, Shehnaaz Suliman and Daniel G. Welch to serve until the 2029 Annual Meeting, and ratified Ernst & Young LLP as the company’s independent auditor for the fiscal year ending December 31, 2026. Investors also backed, on an advisory basis, the company’s executive compensation program, signaling broad shareholder support for Ultragenyx’s current leadership, governance structure and compensation policies. The most recent analyst rating on (RARE) stock is a Buy with a $79.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page. **Spark’s Take on RARE Stock** According to Spark, TipRanks’ AI Analyst, RARE is a Neutral. The score is constrained primarily by weak financial performance: substantial ongoing losses, heavy cash burn, and negative equity with sizable debt. Offsetting factors include constructive technical momentum and a generally positive earnings-call outlook with reaffirmed 2026 guidance, cost-reduction plans, and multiple upcoming regulatory catalysts, though near-term execution and cash-use risk remains significant. To see Spark’s full report on RARE stock, click here. **More about Ultragenyx Pharmaceutical** Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for patients with rare and ultra-rare genetic diseases. The company operates in a highly specialized segment of the pharmaceutical industry, targeting conditions with significant unmet medical need and a concentrated, global patient base. **Average Trading Volume:** 1,902,511 **Technical Sentiment Signal:** Sell **Current Market Cap:** $2.46B Find detailed analytics on RARE stock on TipRanks’ Stock Analysis page. ### Related Stocks - [RARE.US](https://longbridge.com/en/quote/RARE.US.md) ## Related News & Research - [Ultragenyx CFO’s Latest Stock Move Has Investors Buzzing](https://longbridge.com/en/news/285146405.md) - [Ultragenyx Pharmaceutical (RARE) Is Down 31.0% After Rare-Disease Milestone Updates - Has The Bull Case Changed?](https://longbridge.com/en/news/271453846.md) - [How ANI’s Raised 2026 Guidance And Buyback Plan At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story](https://longbridge.com/en/news/286635831.md) - [Sensorion Appoints Fred Chereau as Chief Executive Officer](https://longbridge.com/en/news/286719182.md) - [](https://longbridge.com/en/news/286948461.md)